ECSP22056627A - Anticuerpos contra la integrina alfa 11 beta 1 - Google Patents

Anticuerpos contra la integrina alfa 11 beta 1

Info

Publication number
ECSP22056627A
ECSP22056627A ECSENADI202256627A ECDI202256627A ECSP22056627A EC SP22056627 A ECSP22056627 A EC SP22056627A EC SENADI202256627 A ECSENADI202256627 A EC SENADI202256627A EC DI202256627 A ECDI202256627 A EC DI202256627A EC SP22056627 A ECSP22056627 A EC SP22056627A
Authority
EC
Ecuador
Prior art keywords
beta
antibodies against
integrin alpha
against integrin
antigen
Prior art date
Application number
ECSENADI202256627A
Other languages
English (en)
Inventor
Christopher Beneduce
James W Meador Iii
Elma Kurtagic
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of ECSP22056627A publication Critical patent/ECSP22056627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción incluye anticuerpos que se unen específicamente a la integrina alfa 11 beta 1 (a11B1), así como métodos de elaboración y uso de esos anticuerpos. En algunas modalidades, un anticuerpo anti-a11 p1, o un fragmento de unión al antígeno de este, es un anticuerpo monoclonal, o un fragmento de unión al antígeno de este. La presente descripción también proporciona el uso de esos anticuerpos para tratar cánceres y/o trastornos fibróticos.
ECSENADI202256627A 2019-12-20 2022-07-19 Anticuerpos contra la integrina alfa 11 beta 1 ECSP22056627A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951723P 2019-12-20 2019-12-20
US202062983155P 2020-02-28 2020-02-28
US202063054717P 2020-07-21 2020-07-21

Publications (1)

Publication Number Publication Date
ECSP22056627A true ECSP22056627A (es) 2022-11-30

Family

ID=76478574

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202256627A ECSP22056627A (es) 2019-12-20 2022-07-19 Anticuerpos contra la integrina alfa 11 beta 1

Country Status (18)

Country Link
US (2) US12460006B2 (es)
EP (1) EP4076525A4 (es)
JP (2) JP2023508286A (es)
KR (1) KR20220123013A (es)
CN (1) CN115135342A (es)
AU (1) AU2020407124A1 (es)
BR (1) BR112022012093A2 (es)
CA (1) CA3165386A1 (es)
CL (1) CL2022001673A1 (es)
CO (1) CO2022010204A2 (es)
CR (1) CR20220288A (es)
DO (1) DOP2022000129A (es)
EC (1) ECSP22056627A (es)
IL (1) IL294047A (es)
MX (1) MX2022007521A (es)
PE (1) PE20221723A1 (es)
PH (1) PH12022551471A1 (es)
WO (1) WO2021127500A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230121831A (ko) * 2020-12-18 2023-08-21 모멘타 파머슈티컬스 인코포레이티드 인테그린 알파 11 베타 1에 대한 항체
JPWO2023238845A1 (es) * 2022-06-07 2023-12-14
CA3258452A1 (en) * 2022-06-22 2023-12-28 Momenta Pharmaceuticals, Inc. Antibodies targeting alpha 11 beta 1 integrin and their uses

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
SE9902056D0 (sv) 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2008068481A1 (en) 2006-12-05 2008-06-12 Cartela R & D Ab New compounds, methods and uses
CA2709411A1 (en) 2006-12-18 2008-06-26 Cartela R&D Ab Binding agents to the integrin alpha-11 subunit, and uses thereof
EP3037819A4 (en) 2013-08-23 2017-03-29 Fujita Health University Method of determining resistance to influenza virus
WO2015161247A1 (en) 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
JP7174627B2 (ja) * 2015-10-23 2022-11-17 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用
WO2017201491A1 (en) 2016-05-19 2017-11-23 Momenta Pharmaceuticals, Inc. Methods for treating disorders associated with fibrosis and systemic sclerosis
EP3517549A1 (en) 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
US20230065153A1 (en) 2018-03-01 2023-03-02 Hiroshima University Anti-integrin alpha-11 monoclonal antibody and use thereof
KR20230121831A (ko) 2020-12-18 2023-08-21 모멘타 파머슈티컬스 인코포레이티드 인테그린 알파 11 베타 1에 대한 항체

Also Published As

Publication number Publication date
MX2022007521A (es) 2022-07-19
US12460006B2 (en) 2025-11-04
KR20220123013A (ko) 2022-09-05
JP2025160182A (ja) 2025-10-22
BR112022012093A2 (pt) 2022-08-30
US20260042845A1 (en) 2026-02-12
WO2021127500A1 (en) 2021-06-24
PH12022551471A1 (en) 2023-04-24
US20230050972A1 (en) 2023-02-16
IL294047A (en) 2022-08-01
CR20220288A (es) 2022-10-07
PE20221723A1 (es) 2022-11-04
CL2022001673A1 (es) 2023-02-03
JP2023508286A (ja) 2023-03-02
EP4076525A4 (en) 2024-05-01
DOP2022000129A (es) 2022-10-31
CA3165386A1 (en) 2021-06-24
CO2022010204A2 (es) 2022-10-21
EP4076525A1 (en) 2022-10-26
AU2020407124A1 (en) 2022-07-21
CN115135342A (zh) 2022-09-30
WO2021127500A9 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
CL2020001619A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095)
ECSP21022299A (es) Anticuerpos de anti-cd33 y métodos para usarlos
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
ECSP22055004A (es) Anticuerpos anti?mertk y m?todos de uso de los mismos
MX2021000889A (es) Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
CO2021000386A2 (es) Anticuerpos humanizados contra psma
MX2024008933A (es) Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
MX2021012652A (es) Metodos para el tratamiento de sujetos con artritis psoriasica.
MX2021002647A (es) Metodos de tratamiento de la psoriasis.
BR112023011777A2 (pt) Anticorpos contra integrina alfa 11 beta 1
MX2021009690A (es) Anticuerpo anti-bag2 y metodos de tratamiento del cancer.
MX2025008461A (es) Anticuerpos terapeuticos
AR119982A1 (es) Terapias de combinación con anticuerpos entpd2